In re: REMICADE

  1. October 21, 2019

    3rd Circ. Declines To Reconsider J&J Remicade Antitrust Case

    The full Third Circuit on Monday declined to reconsider a panel's September ruling sending antitrust claims from Rochester Drug Cooperative Inc. over allegedly inflated prices it paid for the Johnson & Johnson immunosuppressant Remicade to arbitration, denying RDC's petition for a rehearing en banc filed earlier this month.

  2. September 13, 2019

    3rd Circ. Sends J&J Remicade Antitrust Fight to Arbitration

    The Third Circuit ruled on Friday that antitrust claims from Rochester Drug Cooperative Inc. over allegedly inflated prices it paid for the Johnson & Johnson immunosuppressant Remicade fell within the scope of an arbitration clause in a distribution agreement between the two companies.

  3. July 09, 2019

    3rd Circ. Suggests Remicade Fight May Require Arbitration

    A Third Circuit panel pressed an attorney for Rochester Drug Cooperative Inc. during a hearing Tuesday over whether antitrust claims involving allegedly inflated prices it paid for the Johnson & Johnson immunosuppressant Remicade fall under an arbitration clause in a distribution agreement between the two companies.